Low‐intensity oral anticoagulation in sickle‐cell disease reverses the prethrombotic state: promises for treatment?
- 1 July 1995
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 90 (3) , 715-717
- https://doi.org/10.1111/j.1365-2141.1995.tb05607.x
Abstract
Increased plasma levels of prothrombin fragment 1 + 2 (F1 + 2) found in patients with sickle-cell disease reflect enhanced endogenous thrombin generation. We postulate that hypercoagulability contributes to vaso-occlusion. The intensity of acenocoumarol treatment required to reduce the F1 + 2 level to 50% of pretreatment level was investigated in seven patients with symptomatic sickle-cell anaemia during steady-state disease for a period of 2 months. All patients had increased levels of F1 + 2 compared with an age-matched control group. Normalization of the F1 + 2 was achieved at a median INR of 1.64 (range 1.18-2.2). It is concluded that low-intensity oral anticoagulation normalizes the hypercoagulability in sickle-cell disease.Keywords
This publication has 8 references indexed in Scilit:
- Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early DeathNew England Journal of Medicine, 1994
- Plasma factor VII and thrombin–antithrombin III levels indicate increased tissue factor activity in sickle cell patientsBritish Journal of Haematology, 1992
- Monitoring "mini-intensity" anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment F1+2 levelsBlood, 1992
- Vascular occlusion in sickle cell disease: current concepts and unanswered questionsBlood, 1991
- The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial FibrillationNew England Journal of Medicine, 1990
- Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.Journal of Clinical Investigation, 1987
- Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetryBlood, 1981
- Long-Term Anticoagulation in Sickle-Cell DiseaseNew England Journal of Medicine, 1963